Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CVS HealthCVS -0.66%75 EV-to-EBITDA is 18.05 as of Jul. 30, 2026, which is 71% above its 10-year median of 10.58. GuruFocus rates CVS with a GF Score™ of 75/100 and a GF Value™ of $77.71 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 15 Healthcare Plans companies, CVS Health ranks worse than 66.67% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CVS Health's enterprise value is $200,977 Mil.
CVS Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $11,132 Mil. Therefore, CVS Health's EV-to-EBITDA for today is 18.05.
The historical rank and industry rank for CVS Health's EV-to-EBITDA or its related term are showing as below:
CVS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.25 Med: 10.58 Max: 21.53
Current: 18.05
During the past 13 years, the highest EV-to-EBITDA of CVS Health was 21.53. The lowest was 7.25. And the median was 10.58.
CVS's EV-to-EBITDA is ranked worse than 66.67% of 15
companies
in the Healthcare Plans industry
Industry Median: 14.63
vs CVS: 18.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
CVS Health (NYSE:CVS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CVS Health's share price for today is $105.22.
CVS Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for CVS Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Healthcare Plans subindustry, CVS Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CVS Health EV-to-EBITDA vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, CVS Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CVS Health's EV-to-EBITDA falls into.
CVS Health's current Enterprise Value is $200,977 Mil.
CVS Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11,132 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVS Health (CVS) has a EV-to-EBITDA of 18.05 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CVS Health. This is 71% above median its historical median of 10.58. Over the past decade, CVS Health's EV-to-EBITDA has ranged from 7.25 to 21.53. According to the industry distribution chart, CVS Health ranks #10 out of 15 companies in the Healthcare Plans industry, placing it in the top 66.7%.
Is CVS Health's EV-to-EBITDA too high?
CVS Health's current EV-to-EBITDA of 18.05 is 71% above median its 10-year median of 10.58. Over the past 10 years, this metric has ranged from a low of 7.25 to a high of 21.53. The Healthcare Plans industry median EV-to-EBITDA is 14.63. CVS Health's value of 18.05 is 23.4% above this industry median. Based on the distribution chart, CVS Health ranks #10 out of 15 companies in the Healthcare Plans industry, which is below the industry midpoint. Overall, CVS Health has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CVS Health's EV-to-EBITDA compare to ELV and CI?
According to the Healthcare Plans industry distribution chart, CVS Health ranks #10 out of 15 companies for EV-to-EBITDA. This places CVS Health in the lower half of its industry. The industry median EV-to-EBITDA is 14.63. CVS Health's value of 18.05 is 23.4% above this benchmark. Historically, CVS Health's own EV-to-EBITDA has ranged from 7.25 to 21.53 over the past decade. While the company's 10-year median is 10.58 vs. the industry median of 14.63, CVS Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Plans company?
The median EV-to-EBITDA among Healthcare Plans companies is 14.63, based on 15 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CVS Health's current EV-to-EBITDA of 18.05 is 23.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CVS Health. For the Healthcare Plans industry, the median EV-to-EBITDA is 14.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CVS Health's current EV-to-EBITDA is 18.05, which is 71% above median its own 10-year median of 10.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CVS Health stock overvalued right now?
Based on GuruFocus' analysis, CVS Health (CVS) is currently considered Significantly Overvalued. The stock's GF Value™ is $77.71, compared to a current price of $105.22 — trading 35.4% above its estimated fair value. The current EV-to-EBITDA is 18.05, which is 71% above median its 10-year median of 10.58 and 23.4% above the Healthcare Plans industry median of 14.63. CVS Health's overall GF Score™ is 75/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CVS Health (CVS), the current EV-to-EBITDA is 18.05 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CVS Health (CVS) Overvalued in 2026?
Based on GuruFocus' analysis, CVS Health stock appears to be overvalued.
The current stock price of $105.22 is trading 35.4% above its estimated GF Value™ of $77.71.
GuruFocus considers CVS Health to be Significantly Overvalued.
Key valuation signals for CVS:
EV-to-EBITDA: 18.05 (71% above median its 10-year median of 10.58)
GF Value™: $77.71 vs. price of $105.22 (35.4% above fair value)
Industry Position: 23.4% above the Healthcare Plans median (#10 of 15)
No single metric tells the full story. See the CVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
75GF Score
Get the complete analysis for CVS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVS has been successfully added to your 
